🧬 SinoBioData Academic Portal
Open AccessDOI: 10.12307/2026.21607Original Research

Visualization analysis of literature on medication-related osteonecrosis of the jaw

Wang Quan¹,Tang Zhenglong¹

School of Stomatology, Guizhou Medical University

Read Executive PreviewQuick FAQ
Visualization analysis of literature on medication-related osteonecrosis of the jaw
Graphical Abstract / Figure
Published In
Chinese Journal of Tissue Engineering Research
Published:January 15, 2026Edition:Vol 1908, Issue 36 • pp. 100-112Citation:Wang Quan et al. (2026), Chinese Journal of Tissue Engineering Research
Impact FactorPremier Chinese Biomedical Journal indexed in SinoBioData: Chinese Journal of Tissue Engineering Research (中国组织工程研究).
Sponsored Research Partner

Key Takeaways & Executive Findings

  • • The top 100 most-cited articles on medication-related osteonecrosis of the jaw (MRONJ) from 2004-2024 accumulated 12,337 citations, with the US, University of London, and Salvatore L. Ruggiero leading in country, institution, and author productivity. • Hot keywords include risk factors, bisphosphonates, cancer, and osteoclasts, with 'Denosumab' as a burst keyword, indicating a shift toward understanding the role of RANKL inhibitors in MRONJ. • High-level evidence (cohort studies, RCTs, systematic reviews, and clinical guidelines) has driven standardization of diagnosis and management, moving from case reports to evidence-based practice. • Future directions emphasize tissue engineering and regenerative medicine, including 3D-printed scaffolds, stem cell therapy, and novel biomaterials, to enhance bone repair and regeneration in MRONJ.
Sponsored Research Highlight

Abstract

BACKGROUND: Bibliometric and visualization analyses of theme-related literature on medication-related osteonecrosis of the jaw are essential for gaining a comprehensive understanding of its research foundation and emerging trends. OBJECTIVE: To reveal research hotspots, current status, and trends in medication-related osteonecrosis of the jaw through bibliometrics, citation analysis, and visualization analysis. METHODS: The top 100 most-cited medication-related osteonecrosis of the jaw research articles published between 2004 and 2024 were retrieved and screened from the Web of Science Core Collection (SCI-Expanded). A bibliometric analysis was conducted to extract and analyze core characteristics such as annual publication volume, countries, institutions, authors, journal sources, and co-citation relationships, followed by the use of CiteSpace 6.4.R1 software to generate knowledge maps, thereby identifying research hotspots and emerging trends. RESULTS AND CONCLUSION: The included literature accumulated a total of 12 337 citations, with an average annual citation frequency of 6.17 per article. The international core collaboration network was stable and close, with the United States, University of London, and Professor Salvatore L. Ruggiero ranking first in high-cited paper output among countries, research institutions, and authors, respectively. Hot keywords mainly included risk factors, bisphosphonates, cancer, and osteoclasts; the burst keyword was predominantly 'Denosumab', and research directions were diversified. The research heat on medication-related osteonecrosis of the jaw generally showed an upward trend, with core focus on pathological mechanisms, risk factors, and treatment strategies. High-level evidence, such as large cohort studies (LOE 2a), high-quality randomized controlled trials (LOE 1b), GRADE systematic reviews and meta-analyses, and clinical practice guidelines, significantly promoted the field's development. Looking forward, tissue engineering and regenerative medicine, including 3D-printed scaffolds, stem cell therapy, novel biomaterials, and in vitro models, are expected to provide breakthrough strategies for bone repair, regeneration, and mechanistic research of medication-related osteonecrosis of the jaw.

1. Introduction

Medication-related osteonecrosis of the jaw (MRONJ) is a metabolic disorder and necrotic disease of the jawbone caused by antiresorptive or antiangiogenic medications, commonly occurring in patients with bone metastases from malignant tumors and osteoporosis [1]. The condition was first systematically reported by Marx in 2003, establishing a direct causal relationship between intravenous zoledronic acid and jaw necrosis [2], after which case reports of bisphosphonate-related osteonecrosis of the jaw significantly increased. As the spectrum of causative drugs expanded, the American Association of Oral and Maxillofacial Surgeons officially revised the disease name to medication-related osteonecrosis of the jaw in 2014 to reflect its multi-drug etiology [3]; the 2022 updated guidelines further integrated advances in bone immunomicroenvironment imbalance mechanisms and bioactive barrier materials for guided bone regeneration, providing a theoretical framework for multidisciplinary collaborative diagnosis and treatment [4]. Against the backdrop of accelerated population aging in China, the high incidence of osteoporosis and malignant tumors has led to a significant increase in the clinical use of bisphosphonates, resulting in a surge in the incidence of MRONJ [5-7]. However, limited awareness among healthcare providers and patients exacerbates the contradiction between high disease risk and low prevention awareness [8-9], posing greater challenges to the prevention and treatment of MRONJ.

In recent years, significant progress has been made in the field of MRONJ research, with scientific literature growing exponentially and the disciplinary knowledge system continuously updated [1,3,10]. Scientific literature, as nodes in the knowledge network, does not exist in isolation but rather forms an interconnected and dynamically evolving knowledge system. Citation relationships among literature reflect the historical development of the discipline and reveal future research directions. In this context, bibliometric and visualization analyses based on high-impact literature have become key tools for dissecting the research foundation and frontier dynamics of MRONJ. CiteSpace software presents potential patterns in literature through knowledge mapping, and its co-citation analysis function can precisely locate core knowledge nodes driving disciplinary evolution. Currently, no bibliometric study on MRONJ has been reported in the China National Knowledge Infrastructure (CNKI) database. Although BAYRAM et al. [11] have conducted a bibliometric analysis based on the Web of Science, their study did not focus on the top 100 most-cited articles, which are crucial for understanding the field's foundational knowledge and evolution.

SinoBioData Interactive Document Reader
Page 1–5 of Preview
100%
Download Full PDF

Loading authentic research manuscript (Pages 1–5)...

Sponsored Research Partner
Cite This Research Paper
Wang Quan, Tang Zhenglong (2026). Visualization analysis of literature on medication-related osteonecrosis of the jaw. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21607
SinoBioData Academic & Legal Disclaimer

Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.

Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.

Frequently Asked Questions

What is medication-related osteonecrosis of the jaw (MRONJ)?

Medication-related osteonecrosis of the jaw (MRONJ) is a condition characterized by necrotic bone in the maxillofacial region, caused by antiresorptive or antiangiogenic medications, such as bisphosphonates and denosumab, commonly used in patients with osteoporosis or cancer.

What are the main research hotspots in MRONJ according to the study?

The main research hotspots include risk factors, bisphosphonates, cancer, and osteoclasts, with a burst keyword of 'Denosumab', indicating a focus on the role of RANKL inhibitors in the pathogenesis and management of MRONJ.

Which countries, institutions, and authors are leading in MRONJ research?

The United States leads in high-cited paper output, the University of London is the top institution, and Professor Salvatore L. Ruggiero is the most prolific author in the field.

What are the future directions for MRONJ treatment?

Future directions include tissue engineering and regenerative medicine approaches, such as 3D-printed scaffolds, stem cell therapy, novel biomaterials, and in vitro models, which aim to improve bone repair and regeneration in MRONJ.

Why is bibliometric analysis important for MRONJ research?

Bibliometric analysis helps identify research trends, key contributors, and knowledge gaps, providing a comprehensive overview of the field's development and guiding future research priorities.

Recommended Scientific Literature & Research Partners

Related Technical Papers & Translations

Research Paper
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.

Read Abstract & PDF
Research Paper
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.

Read Abstract & PDF
Research Paper
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.

Read Abstract & PDF